RVMD

Business Context and Reporting Period

Revolution Medicines, Inc. (RVMD) is a late-stage clinical oncology company focused on developing novel targeted therapies for patients with RAS-addicted cancers. This Form 10-Q covers the quarterly period ended March 31, 2026. The company has no products approved for commercial sale and has incurred net operating losses since its inception in 2014.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Revenue is $0 as the company has no commercial products.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by $240.4 million (113%) compared to Q1 2025, driven primarily by higher operating expenses.
• Operating Expenses: Total operating expenses rose by $204.5 million (85%).
  • R&D Expenses: Increased by $138.2 million (67%) to $344.0 million. This was due to higher clinical trial and manufacturing costs for daraxonrasib ($46.5M increase) and zoldonrasib ($27.6M increase), increased headcount, and a $28.3 million increase in stock-based compensation.
  • G&A Expenses: Increased by $66.2 million (189%) to $101.3 million, largely due to a $34.0 million increase in stock-based compensation and increased commercial preparation activities.
• Non-Operating Items: Non-operating income turned to a net expense of $(8.6) million from income of $27.3 million in the prior year. This shift was caused by a $15.8 million loss from the change in fair value of warrant liability and $12.2 million in interest expense related to the sale of future royalties.
• Stock-Based Compensation: Total stock-based compensation expense surged to $87.3 million from $25.1 million, including approximately $44.6 million in incremental expense related to a modification of the equity compensation program to include retirement benefit provisions.

Guidance, Outlook, and Risks

• Clinical Progress: In April 2026, the company announced topline results from the RASolute 302 Phase 3 trial for daraxonrasib in second-line pancreatic cancer, showing statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to chemotherapy. The company intends to submit data to the FDA for a New Drug Application (NDA).
• Liquidity and Capital Resources: As of March 31, 2026, the company held $1.91 billion in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least 12 months.
  • Recent Financing (Subsequent Event): On April 17, 2026, the company completed concurrent public offerings raising approximately $2.2 billion in gross proceeds ($1.725 billion from common stock and $500 million from 0.50% convertible senior notes due 2033).
  • At-The-Market (ATM) Offerings: During Q1 2026, the company sold shares under its ATM program for net proceeds of $226.7 million.
  • Royalty Financing: In May 2026, the company received a $250 million payment from Royalty Pharma under Tranche 2 of its Royalty Purchase Agreement.
• Risks and Contingencies:
  • Profitability: The company expects to incur losses for the foreseeable future and may never achieve profitability.
  • Regulatory Approval: Success depends on obtaining marketing approval for product candidates, which is uncertain.
  • Legal Proceedings: A shareholder lawsuit regarding the 2021 EQRx merger was resolved in January 2026 with an estimated accrual of $5.0 million.
  • Collaboration Risks: The company terminated a collaboration with Amgen in April 2026 following Amgen's decision to discontinue development of its compound AMG 193.

Investor Verification Checklist

• Capital Runway: Verify the impact of the April 2026 equity and debt offerings on the company's cash runway and dilution profile.
• Royalty Agreement Terms: Review the specific triggers and royalty rates associated with the Royalty Pharma agreement, particularly the impact of the Tranche 2 funding on future revenue sharing.
• Stock-Based Compensation: Assess the sustainability of the $87.3 million quarterly stock-based compensation expense and the implications of the recent equity plan modification.
• Clinical Data: Confirm the detailed data release from the RASolute 302 trial and the timeline for the NDA submission.
• Warrant Liability: Monitor the fair value of the warrant liability, which fluctuates with the stock price and impacted Q1 net loss significantly.